|
Platin kompleksi sentez ve yapi aydinlatma çalişmasi
36
36.
Patel VK, Chudasama UM, Bhattacharya PK. Study of ternary complexes of copper(II) con-
taining tertiary amines and adenosine-5`-triphosphate in dioxan-water media, J. Chem. Soc. Dalton
Trans., 1983; 1091-1093.
37.
Blakeney JS, Reid RC, Le GT, Fairlie DP. Nonpeptidic ligands for peptide-activated G protein-
coupled receptors, Chem. Rev., 2007; 107: 2960-3041.
38.
Dehand J, Jordanov J. Complexes of Pt(II), Pd(II), Rh(I) and Rh(III) with nitrojen and sulfur-
containing hetereocyclic ligands of biological interest. synthesis, characterization and influence of
pH. Inorg. Chim. Acta, 1976: 17;37-44.
39.
Ghosh SP, Bhattacharjee P, Dubey L, Mıshra LK. Complexes of some platinum metals with
imidazole and benzimidazole. J. Indian Chem. Soc., 1977; 54(1-3): 230-238.
40.
Kralingen GV, Reedijk J. Coordination compounds of Pt(II) with the nitrojen-donor ligand N-
methylimidazole as a ligand. Inorg. Chim. Acta, 1978; 30: 171-177.
41.
Kralingen CGV, Ridder JKD, Reedijk J. Coordination compounds od Pt(II) and Pd(II) with
imidazole as a ligand. New synthetic procedures and characterization. Inorg. Chim. Acta, 1979; 36:
69-77.
42.
Graves BJ, Hodgson DJ, Kralingen CG, Reedijk J. Synthesis and structural characterization
of cis-dichlorobis(N-methylimidazole)platinum(II) and cis-dibromobis (N-methylimidazole) plati-
num(II). Inorg. Chem. 1978; 17: 3007-3011.
43.
Fazakerler GV, Kock KR. A
1
H-NMR and
13
C-NMR study of some cis-[Pt(NH
3
)
2
X
2
]Y
2
comp-
lexes (X= Imidazoles, pyrimidines, 3-substituted pyridines, inosine and guanosine; Y= Cl
-
, ClO
4
-
) in
aqueous solutions. Inorg. Chim. Acta, 1979; 36: 13-25.
44.
Dominia E, Varopayev VN, Skvorsov GG, Minakova SM, Çernov BA. Sintez nrotivopuhole-
vaya aktivnost kompleksnih soyedneny Pt(II), Pt(IV), Pd(IV) S 1-vinil-azikami. Khim. –Farm. Zh.,
1985; 17: 700-703.
45.
Massacesi M, Pinna R, Ponticelli G, Puggioni G. Platinum(IV) chloride complexes with hete-
rocyclic ligands. J. Inorg. Biochem., 1987; 29: 95-100.
46.
Ponticelli G, Biddau M, Zakharova A, Tatjanenko LV. Spectroskopic, biological, and anti-
tumor studies on N-ethyl- and N-propylimidazole platinum(II) complexes. J. Inorg. Biochem. 1987;
29: 101-109.
37
47.
Muir MM, Cadiz ME, Baez A. Synthesis and characterization of new platinum(II) complexes
containing thiazole and imidazole donors. Inorg. Chim. Acta, 1988; 151:165-232.
48.
Muir MM, Gomez GM, Cadiz ME, Muir JA. Synthesis and characterization of new plati-
num(II) complexes containin tiyazol and imidazol donors. Inorg. Chim. Acta, 168; 1990: 47-57.
49.
Muir MM, Cox O, Rivera LA, Cadiz ME, Medina E. Synthesis and characterization of new
platinum(II)
complexes
containing
thiazole
and
imidazole
donors
III.
Dichloro-
bis(styrylbenzole)platinum(II) complexes. Inorg. Chim. Acta, 1992; 191: 131-139.
50.
Floris G, Padaglia A, Ponticelli G, Puggioni G. Platinum(IV) complexes with purine or pyrimi-
dine and imidazole derivatives. Transition Met. Chem. 1992; 17: 145-146.
51.
Bloemink MJ, Engelking H, Karentzopoulos S, Krebs B, Reedijk J. Synthesis crystal structu-
re, antitumor activity, and DNA-binding properties of the new active platinum compound (bis-(N-
methylimidazole-2-yl)carbinol)dichloroplatinum(II) lacking a NH moiety, and of the inactive analog
dichloro(N
1
,N
1
-dimethyl-2,2’-biimidazole)platinum Inorg. Chem. 1996; 35: 619-637.
52.
Clement O, Roswak AW, Buncel E. Hydrogen-deuterium exchange studies in platinum(II)
complexes of 1-methylimidazole. J.Am. Chem. Soc., 1996; 118: 612-620.
53.
Baranska H, Kuduk-Jaworska J, Cacciari S. Raman study of neutral platinum-imidazole
complexes. Journal of raman spectroscopy. 1997; 28: 1-8.
54.
Saha B, Ray M, Banerjee P. Interaction of some azole bases with [Pt(dien)Br]+: conductomet-
ric and spectrophotometric studies. Indian J. Chem., 1999; 38A: 656-659.
55.
Pal S, Das D, Chattopadhyay P, Sinha C, Panneerselvam K, Lu TH. Synthesis, spectral and
electrochemical properties of 1-alkyl-2-(naphtyl-β-azo)imidazole complexes of platinum (II) and re-
action with pyridine bases. Single-cyrstal X-ray structure of dichloro- [1-ethyl-2-(naphtyl-β-
azo)imidazole]platinum(II). Polyhedron. 2000; 19: 1263-1270.
56.
Jolley J, Cross WI, Pritchard RG, Mcauliffe CA, Nolan KB. Synthesis and characterization pf
mercaptoimidazole, mercaptopyrimidine and mercaptopyridine complexes of platinum(II) and plati-
num(III). the crystal and molecular structures of tetra(2-mercaptobenzimidazole)-and tetra(2-
mercaptoimidazole)platinum(II) chloride. Inorg. Chim. Acta, 2001; 315: 36-43.
38
57.
Casas JS, Castineiras A, Parajo Y, Perez-Paralle ML, Sanchez A, Sanchez-Gonzales A,
Sordo J. Pd(II) and Pt(II) complexes of 2,2’-biimidazole and its N,N’-dimethyl derivative. The crys-
tal structure of [(PtBr(DMSO))
2
(Me
2
bim)](Me
2
bim=N,N`-dimethyl-2,2`-biimidazole). Polyhedron,
2003:22; 1113-1121.
58.
Oziminski WP, Garnuszek P, Bednarek E, Dobrowolski JC. The platinum complexes with
histamine: Pt(II)(Hist)Cl
2
, Pt(II)(Iodo-Hist)
2
Cl
2
. Inorg. Chim. Acta, 2007; 360:1902-1914.
59.
Taleb RI, Jaramillo D, Wheate NJ, Aldrich-Wright JR. Synthesis of DNA-Sequences-
selective hairpin polyamide platinum complexes. Chem. Eur. J. 2007:13; 3177-3186.
60.
Bakalova A, Varbanov H, Buyukliev R, Momekov G, Ferdinandov D, Konstantinov S, Iva-
nov D. Synthesis, characterization and biological activity of Pt(II) and Pt(IV) complexes with 5-
methyl-5(4)-pyridyl)-2,4-imidazolidenedione. Eur. J. Med. Chem. 2008; 43: 958-965.
61.
Adams CJ, Haddow MF, Hughes RJI, Kurawa MA, Orpen AG. Coordination chemistry of
platinum and palladium in the solid-state: synthesis of imidazole and pyrazole complexes. Dalton
Trans., 2010: 39; 3714-3724.
62.
Kumbhare LB, Singh U, Singh BG, Wadawale A, Kedarnath G, Zade SS, Priyadarsini KI,
Jain VK. Methimazole complexes of platinum(II): synthesis, characterization and redox behavior.
Inorg. Chem. Acta, 2011; 374(1): 69-78.
63.
Ravera M, Gabano E, Sardi M, Ermondi G, Caron G, McGlinchey MJ, Müller-Bunz H,
Monti E, Gariboldi M, Osella D. Synthesis, characterization, structure, molecular modeling studies
and biological activity of sterically crowded Pt(II) complexes containing bis(imidazole) ligands. J.
Inorg. Biochem., 2011; 105: 400-409.
64.
Rabik C, Dolan ME. Molecular mechanisms of resistance and toxicity associated with
platinating agents. Cancer Treat. Rev., 2007; 33: 9-23.
65.
Van den Berg JH, Beijnen JH, Balm AJM, Schellens JHM. Future opportunities in preventing
cisplatin induced ototocixicity. Cancer Treat. Rev., 2006; 32: 390-397.
66.
Abu-Surrah AS, Kettuen M. Platinum group antitumor chemistry: Design and development of
new anticancer drugs complementary of cisplatin. Curr. Med. Chem., 2006; 13: 1337-1357.
39
67.
Bernhardt G, Brunner H, Gruber N, Lottner C, Pushpan SK, Tsuno T, Zabel M. Carbopla-
tin derivatives with superior antitumor activity compared to the parent compound. Inorg. Chim. Acta,
2004; 357: 4452-4466.
68.
Pavelka M, Lucas MFA, Russo N. On the hydrolysis mechanism of the second-generation anti-
cancer drug carboplatin. Chem-Eur. J., 2007; 13: 10108-10116.
69.
Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in
cancer treatment. Crit. Rev. Oncol. Hema., 2002; 42: 317-325.
70.
Fanelli M., Formica M., Fusi V., Giorgi L., Micheloni M. Coord Chem Rev,
2016;310:41-79.
71.
Kostova I. Platinum complexes as anticancer agents, Recent Pat Anti-Canc, 2006; 1:
1-22.
72.
Sen VD, Golubev VA, Volkova LM, Konovalova NP, Synthesis and antitumor acti-
vity of platinum(II) complexes with trans-3,4-diamino-2,2,6,6-tetramethypiperidine-1-oxyl.
J. Inorg. Biochem., 1996; 64: 69-77.
73.
Khan SRA, Guzman-Jimenez I, Whitmire KH, Khokhar AR. Synthesis and charac-
terization of platinum(II) complexes with 3-methylpiperidine)
2
(malonato)·H
2
O. Polyhed-
ron, 2000; 19: 983-989.
74.
Rochon FD, Gruia LM. Synthesis and characterization of Pt(II) complexes with ami-
ne
and
carboxylate
ligands.
Crystal
structure
of
(1,1-
cyclobutanedicarboxlato)di(ethylamine) platinum(II)·H
2
O. Inorg. Chim. Acta, 2000; 306:
193-204.
75.
Mukhopadhyay U, Thurston JH, Whitmire KH, Sidik ZH, Khokhar AR. Prepara-
tion, characterization and antitumor activity of new cisplatin analogues with 1-methyl-
4(methylamino)piperidine:
Crystal
structure
of
[Pt
II
(1-methyl-4-
(methylamino)piperidine)(oxalate)]. J. Inorg. Biochem., 2003; 94: 179-185.
76.
Crul M, Waardenburg RCAM, Beijnen JH, Schellens JHM. DNA-based drug inte-
raction of cisplatin. Cancer Treatment Rev., 2002; 28: 291-303.
77.
Jamieson EJ, Lippard SJ. Structure, recognition and processing of cisplatin-DNA
adducts. Chem. Rev., 1999; 99: 2467-2498.
40
78.
Güney S, Güney N, Sönmez NC, Ergenekon E. Risk-adapted management for pati-
ens with clinical stage 1 non-seminomatous germ cell tumour of the testis. Med Oncol.,
2009; 26(2), 136-142.
79.
Dasari S., Tchounwou P.B. Eur J Pharm, 2014; 740: 364-378.
80.
Reedijk J. Why does cisplatin reach guanine-N7 with competing S-donor ligands avai-
lable in the cell?. Chem. Rev., 1999; 99: 2499-2510.
81.
Petrović D, Stojimirovic B, Petrović B, Bugarćić ZM, Bugarćić ZD. Studies of inte-
ractions between platinum(II) complexes and some biologically relevant molecules.
Bioorg. Med. Chem., 2007; 15: 4203-4211.
82.
Reedijk J. The relevance of hydrogen bonding in the mechanism of action of platinum
antitumor compounds. Inorg. Chim. Acta, 1992; 198-200: 873-881.
83.
Hall MD, Hambley TW. Platinum(IV) antitumor compounds: their bioinorganic che-
mistry. Coordin. Chem. Rev., 2002; 232: 49-67.
84.
Sadowitz PD, Hubbard BA, Dabrowiak JC, Goodisman J, Tacka KA, Aktas MK, Cun-
nıngham MJ, Dubowy RL, Souid AK. Kinetics of cisplatin binding to celluar DNA and modulati-
ons by thiol-blocking agents and thiol drugs, British, J. Pharm., 2002; 30(2): 183-190.
85.
Shen D, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense
mechanism resulting from multiple epigenetic and genetic changes. Pharmacological Rev., 2012; 64:
706-721.
86.
Fuertes MA, Alonso C, Perez JM. Biochemical modulation of cisplatin mechanisms of action:
Enhancement of antitumor activity and circumvention of drug resistance. Chem. Rev., 2003; 103:
645-662
87.
Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity.
Toxins. 2010; 2: 2490-2518.
88.
Kuo MT, Fu S, Savaraj N, Chen HHW. Role of the human high-affinity copper transporter
(hCtr1) in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. Cancer
Res. 2012; 72: 4616-4621.
41
89.
Reedijk J. New clues for platinum antitumor chemistry: kinetically controlled metal binding to
DNA, Proc. Natl. Acad. Sci. USA, 2003;100(7): 3611-3616.
90.
Chválová K, Brabec V, Kašpárková J. Mechanism of the formation of DNA-protein cross-
links by antitumor cisplatin. Nucleic Acids Res. 2007; 35: 1812-1821.
91.
Hartley FR. Palladium and platinum. Coordin. Chem. Rev., 1985; 67: 1-108.
92.
Chanoler PA. Palladium and platinum. Coordin. Chem. Rev., 1986; 71: 235-382.
93.
Takahara PM, Frederik CA, Lippard SJ. Crystal structure of the anticancer drug
cisplatin bound to duplex DNA. J. Am. Chem. Soc., 1996; 118: 12309-12321.
94.
Fichtinger-Schepman AMJ, Van der Veer JL, den Hartog JHJ, Lohman PHM,
Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA:
Formation identification, and quantitation. Biochemistry, 1985; 24: 707-713.
95.
Lovejoy KS, Lippard SJ. Non-traditional platinum compouds for improved accumu-
lation, oral bioavailability, and tumor targeting. Dalton Trans 2009;48:10651-10659.
96.
Starha P., Travnicek Z., Popa I. Platinum(II) oxalato complexes with adenine-based
carier ligands showing significant in vitro antitumor activity. Journal of Inorg Biochem.
2010;104:639-647.
97.
Rabiger DJ, Joullıe MM. The ionization constants, ultraviolet and infrared spectra
of some substituted benzimidazoles. J. Org. Chem. 1964; 29: 476-482.
42
ÖZGEÇMİŞ
Emine Merve ERTUĞRUL 24/03/1992, Merkez/Mersin ’de doğdu.
İlköğrenimini Osman Düşüngel İlköğretim, Viranşehir 75. Yıl İlköğretim okullarında
okudu. Kayseri Kocasinan Anadolu Lisesinin sayısal bölümünde lise öğrenimini 2010
yılında tamamladı. 2011 yılında Mersin Üniversitesi Eczacılık Fakültesinde lisans
eğitimine başladı.
Dostları ilə paylaş: |
|
|